News Update: GenoBioTX and Crown Bioscience Sign Global Cooperation Agreement

                                                            20240627

GenoBioTX and Crown Bioscience have entered into a five-year global partnership, enhancing their existing collaboration. This agreement leverages GenoBioTX's vast animal model resources and Crown Bioscience's specialized immuno-oncology platform to deliver superior model resources and CRO services.

GenoBioTX will share its library of over 11,000 standardized genetically engineered mouse models with Crown Bioscience and provide development services for these models and cell lines. This collaboration aims to advance immuno-oncology research and bridge the gap between scientific discovery and clinical application, invigorating the global biopharmaceutical industry.

About Crown Bioscience

Founded in 2006, Crown Bioscience is now a subsidiary of JSR Life Sciences. Headquartered in San Diego, California, Crown Bioscience operates 13 subsidiaries and R&D centers across the Americas, Europe, and Asia, employing over 1,200 people globally. As a preclinical CRO, Crown Bioscience specializes in providing preclinical and translational medicine platform services, focusing on oncology and immuno-oncology drug discovery and development. The company boasts an extensive, commercially viable PDX model library worldwide. Exclusively licensed by the Netherlands' HUB, Crown Bioscience offers tumor organoid commercialization services. Notably, in 2021, Crown Bioscience contributed to the approval of 6 out of 13 oncology drugs by the FDA. Crown Bioscience assists clients in selecting effective cancer drug candidates, ensuring timely and effective treatment for patients.